ColoSeq Tumor Panel
General Information
- Lab Name
- ColoSeq Tumor Panel
- Lab Code
- CSQTP
- Epic Ordering
-
Order using "UW Genetics and Solid Tumor Test Request"
Place a separate order to draw the paired blood sample.
See tip sheet for more information (internal link).
- Description
ColoSeq™ Paired Tumor-Germline Panel is designed to resolve unexplained mismatch repair deficiency by performing targeted tumor sequencing for somatic mismatch repair (MMR) mutations which have been reported in cancers with IHC loss of MMR protein(s) and normal (negative) germline MMR gene testing. ColoSeq™ Tumor Panel includes both a comprehensive pan-cancer germline analysis of 91 genes associated with hereditary cancer syndromes AND a targeted tumor assessment of select somatic and constitutionally mosaic somatic mutations to aid in the evaluation of mismatch repair deficiency. The tumor analysis includes microsatellite instability, detection of loss of heterozygosity and BRAF V600E mutation.
ColoSeq™ Tumor Panel resolves unexplained mismatch repair deficiency in more than 90% of patients who have mismatch repair deficient tumors and negative germline testing. All exons and flanking intronic sequences are analyzed for all panel genes. Complete promoter and intronic sequencing of the mismatch repair genes, as well as BRCA1/2, is performed, and non-coding variants of uncertain significance are assessed with RNA analysis when certain criteria are met. Select patients may be offered long range sequencing. Many patients undergoing paired tumor-germline testing have already undergone a lot of testing, and these assays are intended to provide conclusive results whenever possible.
ColoSeq™ Tumor assay is not intended to evaluate for somatic mutations for purposes of cancer treatment. Analysis for these tests is limited to select somatic and constitutional mosaic mutations to aid in the diagnosis of genetic and/or hereditary conditions and not all somatic mutations detected are reported.ColoSeq™ Tumor Panel uses next-generation sequencing to detect most mutations in AKT1, ALK, APC, ATM, ATR, AXIN2, BAP1, BARD1, BMPR1A, BRAF, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDK12, CDKN1B, CDKN2A, CEBPA, CHEK2, CTNNA1, CTNNB1, DDX41, DICER1, EGFR, EPCAM, ETV6, FANCM, FH, FLCN, GATA2, GEN1, GREM1, HOXB13, KIF1B, KIT, LZTR1, MAX, MBD4, MEN1, MET, MITF, MLH1, MLH3, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PDGFRA, PHOX2B, PIK3CA, PMS2, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD51B, RAD51C, RAD51D, RB1, RECQL, RET, RINT1, RNF43, RPS20, RSPO3, RUNX1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, SUFU, STK11, TMEM127, TP53, TSC1, TSC2, VHL, and WT1.
Next-generation sequencing is performed on an Illumina instrument to detect single nucleotide variants, insertions, deletions, gene amplifications, and selected translocations.
NOTE: A germline sample is required if germline BROCA or ColoSeq ™ testing was not performed previously at the University of Washington. The germline sample is used to evaluate for the presence of the apparently somatic mutations detected in the tumor, including the identification of constitutional mosaicism. Approximately 7% of patients with prior negative germline testing are found to have a previously undetected pathogenic germline variant or constitutional mosaic mutation in one of the MMR genes.
For an overview of available germline and paired tumor-germline testing for hereditary cancer syndromes, please see: Hereditary Cancer Test Menu: Germline and Paired Tumor-Germline guideline.
ColoSeq Polyposis [CSQP] is available for the evaluation of unexplained polyposis.
ColoSeq Tumor Single Gene [CSQTS] is also available for the analysis of single gene(s) from the ColoSeq™ Tumor Panel.ColoSeq™ Panel Genes
Gene
Function/Pathway
Heterozygote Cancer Risk*
Associated disease/syndrome
References
ALK
MYC signaling Neuroblastoma Cowden-like
18724359, 28674118 AKT1
AKT signaling Breast, Thyroid Cowden-like
23246288 APC
WNT signaling Colon Familial adenomatous polyposis
20301519 ATM
Double stranded break repair Breast, Pancreatic Ataxia telangiectasia (recessive)
16832357, 19781682, 22585167 ATR
Double stranded break repair Oropharyngeal Seckel (recessive)
22341969 AXIN2
WNT signaling Colon Colon cancer, oligodontia
15042511 BAP1
BRCA1-associated protein complex Uveal Melanoma, Mesothelioma BAP1 Tumor predisposition syndrome
21874000, 21874003 BARD1
BRCA1-associated protein complex Breast, Ovarian Hereditary breast cancer
21344236 BMPR1A
TGF-beta signaling Colon Juvenile Polyposis
20301642 BRAF
Serine/Threonine protein kinase Typically somatic or mosaic only Typically somatic only, association with MLH1 promoter hypermethylation in colon cancer and Cardiofaciocutaneous syndrome when mosaic
20301365 BRCA1
BRCA1-associated protein complex Breast, Ovarian Hereditary breast and ovarian cancer
22006311,2270482,7545954 BRCA2
Fanconi/BRCA Breast, Ovarian Hereditary breast and ovarian cancer, Fanconi anemia FA-D1 (recessive)
22006311,8524414 BRIP1
Fanconi/BRCA Breast, Ovarian Fanconi anemia FA-J (recessive)
22006311,17033622,21964575 CDH1
Cell adhesion Breast, Gastric Hereditary diffuse gastric cancer
20301318 CDK4
Cell cycle Melanoma Familial melanoma
19585149 CDK12
MAP kinase regulation Breast, Ovarian Typically somatic only; Hereditary breast and ovarian cancer
24554720,29906450,24240700 CDKN1B
Cyclin-dependent kinase inhibitor 1B Parathyroid, Pituitary Multiple endocrine neoplasia, type IV
37733893 CDKN2A
Cell cycle Pancreatic, Melanoma Familial melanoma and pancreatic cancer
19585149 CEBPA
Tumor suppressor Leukemia Familial AML
35178345 CHEK2
Double stranded break repair Breast Hereditary breast cancer 11967536 CTNNA1
Beta-catenin, e-cadherin complex Gastric Hereditary diffuse gastric cancer
23208944 CTNNB1
WNT signaling Typically somatic only Colon cancer, endometrial cancer, desmoid tumors, colon adenomas
33115416, 37048063 DDX41
Splicing regulation Leukemia, MDS Familial MDS, AML
26712909,34723452 DICER1
Tumor suppressor Wilms tumor, Pleuropulmonary blastoma DICER1 syndrome
29343557,28960912,23625684 EGFR
Epidermal growth factor receptor Lung Familial lung cancer
37274482 EPCAM
Deletions inactivate MSH2, mismatch repair Colon, Ovarian, Endometrial Lynch syndrome
23938213 ETV6
Transcription factor in hemopoietic regulation Leukemia, MDS Familial thrombocytopenia, MDS, acute leukemia
28555414 FANCM
Fanconi/BRCA Breast Fanconi anemia (recessive)
25288723 FH
Tumor suppressor Renal Hereditary leiomyomatosis and renal cell cancer
25018647,11865300,25004247 FLCN
Tumor suppressor Renal Birt-Hogg-Dube syndrome. Primary spontaneous pneumothorax.
12204536, 19659657 GATA2
Transcription factor in hemopoietic regulation Leukemia, MDS Familial leukemia, MDS, immunodeficiency
38660832, 36455197 GEN1
Double stranded break repair Breast Hereditary breast cancer
20512659 GREM1
BMP antagonist Colon Hereditary mixed polyposis syndrome
22561515 HOXB13
Sequence-specific transcription factor which binds preferentially to methylated DNA Prostate Familial prostate cancer
36446039, 34799695, 34059701 KIF1B
Tumor suppressor Neuroblastoma Hereditary neuroblastoma
18334619, 24469107, 30859632 KIT
Proto-oncogene which encodes a tyrosine-protein kinase that acts as a cell-surface receptor for cytokine KITLG/SCF Gastrointestinal stromal tumors (GIST), Acute myelogenous leukemia (AML) Hereditary GIST and AML
36351335, 35821557 LZTR1
RAS ubiquitination/MAPK signaling Schwannomatosis Schwannomatosis, Noonan syndrome
24362817, 25335490 MAX
MYC signaling Pheochromocytoma, Paraganglioma Hereditary pheochromocytoma and paraganglioma
21685915, 22452945 MBD4
Mismatch DNA repair Uveal Melanoma, myelodysplastic disease, colon polyposis Polyposis, multi-organ tumor predisposition (recessive)
32239153, 35460607, 30049810 MEN1
Gene expression regulation Endocrine Multiple endocrine neoplasia type 1
9215689 MET
Tyrosine Kinase receptor Kidney, Squamous cell carcinomas Hereditary papillary renal cell carcinoma
11551094,9140397,27330189 MITF
Melanocyte inducing transcription factor Kidney, Melanoma MITF-related melanoma and renal cell carcinoma predisposition
24290354,22012259 MLH1
Mismatch DNA repair Colon, Ovarian, Endometrial Lynch syndrome
20301390 MLH3
Mismatch DNA repair Polyposis (recessive) unknown
30573798 MSH2
Mismatch DNA repair Colon, Ovarian, Endometrial Lynch syndrome
20301390 MSH3
Mismatch DNA repair Polyposis Familial adenomatous polyposis 4 (recessive)
27476653, 35675019, 38243056 MSH6
Mismatch DNA repair Colon, Endometrial Lynch syndrome
20301390 MUTYH
DNA repair Colon MUTYH-associated polyposis (recessive)
20301519, 21952991 NBN
Double stranded break repair Breast Nijmegen breakage syndrome (recessive)
15185344,9590180 NF1
MAPK signaling Optic Glioma, Peripheral Nerve Sheath, Breast Neurofibromatosis
2114220, 23165953, 20301288 NF2
Cellular regulation Acoustic neuromas, Vestibular Schwannomas Neurofibromatosis
20301380 NTHL1
Base excision repair Colon polyps, Endometrial, Breast, Pancreatic Hereditary cancer with colon polyposis (recessive)
25938944, 26431160 PALB2
Fanconi/BRCA Breast, Pancreatic Fanconi anemia FA-N (recessive)
17200668,17200671,25099575 PDGFRA
Protein tyrosine kinase GIST, often somatic Familial, sporadic GIST
25975287, 23036227 PHOX2B
Tumor suppressor Neuroblastoma Hereditary neuroblastoma
17637745,28674118 PIK3CA
AKT signaling Breast, Thyroid Cowden-like
22729224, 23246288 PMS2
Mismatch DNA repair Colon, Endometrial Lynch syndrome
20301390 POLD1
DNA Polymerase Colon, Endometrial Familial polyposis, colorectal cancer
23263490, 23770608 POLE
DNA Polymerase Colon Familial polyposis, colorectal cancer
23263490 POT1
Telomere maintenance Melanoma, CLL, Sarcoma, Glioma, Colon, Thyroid, Breast Multi-organ tumor predisposition
23502782, 24686849, 28853721, 37140166 PRKAR1A
cAMP signaling Endocrine Carney complex (recessive) 4010501 PTCH1
Hedgehog Basal cell carcinoma, PNET Nevoid basal cell-carcinoma syndrome
8681379, 8658145, 20301330 PTEN
PI3K/MAPK Signaling Breast Cowden syndrome
20301661 RAD51B
Double stranded break repair Unknown Hereditary breast and ovarian cancer 24139550 RAD51C
Fanconi/BRCA Ovarian, Breast Hereditary breast and ovarian cancer 22006311,22538716 RAD51D
Fanconi/BRCA Ovarian, Breast Fanconi anemia FA-O (recessive) 21822267,22415235 RB1
Tumor suppressor Retinoblastoma, Sarcoma, Melanoma Fanconi anemia (recessive) 25621664,22355046,20301625 RECQL
DNA repair Breast Hereditary retinoblastoma 25915596 RET
Receptor Tyrosine Kinase Endocrine Hereditary breast cancer 20301434 RINT1
DNA checkpoint regulation Breast, Colon Multiple endocrine neoplasia type 2 25050558 RNF43
WNT signaling Colon Sessile Serrated Polyposis
27329244, 27081527 RPS20
Ribosomal protein Colon unknown
24941021 RSPO3
WNT signaling Typically somatic only Colon cancer 29127379, 37048063 RUNX1
Hematopoietic stem cell regulation (transcription factor) myelodysplastic syndrome and acute myeloid leukemia RUNX1-familial platelet disorder
21148331 SDHA
Succinate dehydrogenase complex Pheochromocytoma, Paraganglioma Hereditary paraganglioma-pheochromocytoma
20484225, 21752896 SDHAF2
Succinate dehydrogenase complex Pheochromocytoma, Paraganglioma Hereditary paraganglioma-pheochromocytoma
20301715 SDHB
Succinate dehydrogenase complex Pheochromocytoma, Paraganglioma Hereditary paraganglioma-pheochromocytoma
11404820 SDHC
Succinate dehydrogenase complex Pheochromocytoma, Paraganglioma Hereditary paraganglioma-pheochromocytoma
11062460 SDHD
Succinate dehydrogenase complex Pheochromocytoma, Paraganglioma Hereditary paraganglioma-pheochromocytoma
10657297 SMAD4
TGF-beta signaling Colon Juvenile Polyposis
20301642 SMARCA4
SWI/SNF complex Ovarian Ovarian
Hereditary small cell carcinoma of the ovary, hypercalcemic24658002 SMARCB1
ATP-dependent SWI/SNF chromatin remodeling complex Schwannoma, Rhabdoid tumors, Meningioma Schwannomatosis; Rhabdoid tumor predisposition syndrome type 1 28109176, 29706634 SMARCE1
DNA repair and replication Spinal meningioma Familial spinal meningioma 23377182 STK11
Tumor suppressor Breast, Colon, Pancreatic, Gastric, Hamartomas Peutz-Jeghers syndrome 20301443 SUFU
Hedgehog Signaling Basal cell carcinoma, Medulloblastoma, Meningioma, Gonadal tumors Nevoid basal cell-carcinoma syndrome (Gorlin syndrome) 19533801, 35768194 TMEM127
Tumor suppressor Pheochromocytoma, Paraganglioma Hereditary paraganglioma-pheochromocytoma 20301715 TP53
Cell growth Breast, Ovarian Li-Fraumeni syndrome
22006311, 20301488 TSC1
Cell growth Hamartomas Tuberous sclerosis complex
10227394,9924605,17287951 TSC2
Cell growth Hamartomas Tuberous sclerosis complex
8825048,9829910 VHL
p53 regulation Kidney, Neuroendocrine von Hippel-Lindau syndrome
20301636 WT1
WT1 transcription factor Wilms tumor Wilms tumor
15150775 For previous versions of ColoSeq™ - Lynch and Polyposis Panel, see Previous Versions, COSEQ.
- References
- Pritchard CC, et al. ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn 2012, 14:357-66. 22658618
- Walsh T, et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci U S A 2010, 107:12629-33. 20616022
- Nord AS, Lee M, King MC, and Walsh T. Accurate and exact CNV identification from targeted high-throughput sequence data. BMC Genomics 2011, 12:184. 21486468
- Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet 2010, 11:31-46. 19997069
- Rhees J, Arnold M, and Boland CR. Inversion of exons 1-7 of the MSH2 gene is a frequent cause of unexplained Lynch syndrome in one local population. Fam Cancer 2014, 13:219-25. 24114314
- Mensenkamp AR, et al. Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors. Gastroenterology 2014, 146:643-646.e8. 24333619
- Haraldsdottir S, et al. Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. Gastroenterology 2014, 147:1308-1316.e1. 25194673
- Salipante SJ, Scroggins SM, Hampel HL, Turner EH, and Pritchard CC. Microsatellite instability detection by next generation sequencing. Clin Chem 2014, 60:1192-9. 24987110
- Forms & Requisitions
Requisition Form and Ordering Instructions:
1. Fill out a Genetics Requisition Form
Providers with access to the UW implementation of Epic (i.e., FHCC, HMC, SCCA, UWMC, UWNW) may order this test using the order "UW Genetics and Solid Tumor Test Request." See tip sheet for more information (internal link).
2. Check "ColoSeq™ – Tumor Panel" or "ColoSeq™ - Tumor Single Gene" as desired.
3. For ColoSeq™ - Tumor Single Gene, specify gene in space provided.
4. Unless prior germline testing was performed at University of Washington, also select: "Normal Control (blood)."
5. Select the appropriate “Specimen Submitted."
6. Submit test requisition with peripheral blood sample and a copy of the tumor pathology report.
NOTE: Tumor specimen will be requested directly, by UW Laboratory Medicine and Pathology, from the originating pathology department, and therefore, in most cases, it is not necessary to submit tumor block or slides.
- Synonyms
- AKT1, ALK, APC, ATM, ATR, AXIN2, BAP1, BARD1, biallelic somatic, BMPR1A, BRAF, BRCA1, BRCA2, BRIP1, CDH1, CDK12, CDK4, CDKN1B, CDKN2A, CEBPA, CHEK2, CTNNA1, CTNNB1, DDX41, DICER1, double somatic, EGFR, EPCAM, ETV6, FANCM, FH, FLCN, GATA2, GEN1, GREM1, HOXB13, KIF1B, KIT, Lynch syndrome, LZTR1, MAX, MBD4, MEN1, MET, mismatch repair deficiency, MITF, MLH1, MLH3, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PDGFRA, PHOX2B, PIK3CA, PMS2, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD51B, RAD51C, RAD51D, RB1, RECQL, RET, RINT1, RNF43, RPS20, RSPO3, RUNX1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, STK11, SUFU, TMEM127, TP53, TSC1, TSC2, VHL, WT1
- Components
-
Code Name CTPGS ColoSeq Tumor Gene Sequenced CTPRE ColoSeq Tumor Result CTPIN ColoSeq Tumor Interpretation CTPCH ColoSeq Tumor Clinical History CTPMT ColoSeq Tumor Methods CTPDI ColoSeq Tumor Director
Interpretation
- Method
Next-generation sequencing.
This assay sequences all exons, flanking intronic splice site sequences, and select promoter regions of AKT1, ALK, APC, ATM, ATR, AXIN2, BAP1, BARD1, BMPR1A, BRAF, BRCA1*, BRCA2*, BRIP1, CDH1, CDK4, CDK12, CDKN1B, CDKN2A, CEBPA, CHEK2, CTNNA1, CTNNB1, DDX41, DICER1, EGFR, EPCAM, ETV6, FANCM, FH, FLCN, GATA2, GEN1, GREM1, HOXB13, KIF1B, KIT, LZTR1, MAX, MBD4, MEN1, MET, MITF, MLH1*, MLH3, MSH2*, MSH3, MSH6*, MUTYH, NBN, NF1, NF2, NTHL1, PALB2, PDGFRA, PHOX2B, PIK3CA, PMS2*, POLD1, POLE, POT1, PRKAR1A, PTCH1, PTEN, RAD51B, RAD51C, RAD51D, RB1, RECQL, RET, RNF43, RPS20, RSPO3, RUNX1, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, SMARCB1, SMARCE1, SUFU, STK11, TMEM127, TP53, TSC1, TSC2, VHL, and WT1.
Gene introns are also sequenced for genes indicated above with an asterisk (*).Sequences are aligned to the human genome reference (HG38). Test performed by targeted capture for listed genes followed by next-generation sequencing with Illumina technology. This test was developed and its performance characteristics determined by the University of Washington Department of Laboratory Medicine. It has not been cleared or approved by the US Food and Drug Administration. This laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA) as qualified to perform high complexity clinical laboratory testing. This test is used for clinical purposes. It should not be regarded as investigational or for research.
- Reference Range
- See individual components
- Ref. Range Notes
No mutations detected.
- References
- Pritchard CC, et al. ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn 2012, 14:357-66. 22658618
- Walsh T, et al. Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci U S A 2010, 107:12629-33. 20616022
- Nord AS, Lee M, King MC, and Walsh T. Accurate and exact CNV identification from targeted high-throughput sequence data. BMC Genomics 2011, 12:184. 21486468
- Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet 2010, 11:31-46. 19997069
- Rhees J, Arnold M, and Boland CR. Inversion of exons 1-7 of the MSH2 gene is a frequent cause of unexplained Lynch syndrome in one local population. Fam Cancer 2014, 13:219-25. 24114314
- Mensenkamp AR, et al. Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors. Gastroenterology 2014, 146:643-646.e8. 24333619
- Haraldsdottir S, et al. Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. Gastroenterology 2014, 147:1308-1316.e1. 25194673
- Salipante SJ, Scroggins SM, Hampel HL, Turner EH, and Pritchard CC. Microsatellite instability detection by next generation sequencing. Clin Chem 2014, 60:1192-9. 24987110
- Guidelines
Ordering & Collection
- Specimen Type
- Formalin-Fixed Paraffin Embedded Tumor Tissue (FFPE), Purified DNA, Peripheral Blood, cultured cells from skin biopsy, purified DNA from peripheral blood or cultured cells, saliva
- Collection
-
Tumor specimen will be requested directly, by UW Laboratory Medicine, from the originating pathology department. In order to facilitate this, a pathology report should be submitted with the test requisition, blood control and other clinical and billing paperwork.
NOTE: This test requires BOTH tumor tissue and peripheral blood. Only tumor tissue is required if ColoSeq™ testing on peripheral blood has been done previously at UW Lab Medicine.
Tumor Tissue:
Tumor specimen will be requested directly, by UW Laboratory Medicine, from the originating pathology department. In order to facilitate this, a pathology report should be submitted with the test requisition, blood control and other clinical and billing paperwork.
If the tumor specimen is being submitted by the ordering provider, tissue samples (FFPE) either (a) slides, OR (b) tissue block are required.
(a) Instructions for slide specimens: 1 slide at 4-micron thickness stained with hematoxylin-and-eosin AND 20 unstained, non-baked slides at 10-micron thickness (a minimum of 10 unstained slides is acceptable). Unstained slides can be on charged or uncharged slides. Note: Sections should contain as much tumor tissue as possible.
(b) Instructions for tissue block specimen: Provide complete tissue block containing tumor tissue. If there is more than one tissue block, please provide the block that has the greatest amount of tumor tissue. Tissue block will be returned at completion of testing. Ship at room temperature.
NOTE: If germline MMR testing was performed in a different laboratory, a peripheral blood sample should be submitted in addition to tumor tissue.
Germline control sample:
BLOOD:
- 10 mL whole blood in LAVENDER TOP EDTA tube.
- Also acceptable: YELLOW TOP ACD tube, purified DNA from peripheral blood or cultured cells.
SALIVA:
Contact laboratory for validated collection kit.SKIN BIOPSY:
- Collection and transport: Obtain 2-4 mm punch biopsy of skin sample under sterile conditions and place in transport media (e.g. Alpha-MEM media, RPMI). Transport media can be supplied by the lab; call 206-598-4488 to request. If transport media is not available, the following media are acceptable alternatives if shipping time will not exceed 24 hours: lactated Ringer's solution, viral transport medium, or sterile saline. DO NOT USE formaldehyde, formalin, alcohol, or 5% dextrose, or tissue culture medium buffered with bicarbonate.
CULTURED CELLS:
- (2) T23 or (1) T75 flask (minimum 1-T25 flask).
- Forms & Requisitions
Requisition Form and Ordering Instructions:
1. Fill out a Genetics Requisition Form
Providers with access to the UW implementation of Epic (i.e., FHCC, HMC, SCCA, UWMC, UWNW) may order this test using the order "UW Genetics and Solid Tumor Test Request." See tip sheet for more information (internal link).
2. Check "ColoSeq™ – Tumor Panel" or "ColoSeq™ - Tumor Single Gene" as desired.
3. For ColoSeq™ - Tumor Single Gene, specify gene in space provided.
4. Unless prior germline testing was performed at University of Washington, also select: "Normal Control (blood)."
5. Select the appropriate “Specimen Submitted."
6. Submit test requisition with peripheral blood sample and a copy of the tumor pathology report.
NOTE: Tumor specimen will be requested directly, by UW Laboratory Medicine and Pathology, from the originating pathology department, and therefore, in most cases, it is not necessary to submit tumor block or slides.
- Handling Instructions
Attach a copy of the pathology report for the tumor sample being submitted.
Ship specimen at room temperature for overnight delivery.
Blood specimens can be held for up to 7 days before shipping if refrigerated.
Ship specimens to:
UW MEDICAL CENTER
LABORATORY MEDICINE - GENETICS LAB
1959 NE PACIFIC ST, ROOM NW220
SEATTLE, WA 98195-7110
- Quantity
-
requested: Entire sample
minimum: Tissue: 10 unstained slides plus one H&E-stained; slide or extracted DNA: 5 microgram AND 5 mL control peripheral blood (DNAPRP)
Processing
- Processing
Blood: Refrigerate whole blood
Unacceptable Conditions: Frozen or clotted specimens
Stability (collection to initiation of testing): Ambient: 5 days; Refrigerated: 7 days; Frozen: Unacceptable
Purified DNA: Refrigerate DNA specimens. Frozen is acceptable.
Performance
- LIS Dept Code
- Genetics (GEN)
- Performing Location(s)
-
UW-MT Genetics Attention: Genetics Lab
Clinical lab, Room NW220
University of Washington Medical Center
1959 NE Pacific Street
Seattle, WA 98195Tel: 206-598–6429 M–F (7:30 AM–4:00 PM)
Fax: 206-616-4584
Lab email: cgateam@uw.eduTel (EXOME only): 206-543-0459
Faculty
Jillian Buchan, PhD, FACMG
Runjun Kumar, MD, PhD
Regina Kwon, MD, MPH
Christina Lockwood, PhD, DABCC, DABMGG
Abbye McEwen, MD, PhD
Colin Pritchard, MD, PhD
Vera Paulson, MD, PhD
Eric Konnick, MD, MS
He Fang, PhD - Frequency
- Results within 4-6 weeks, once sample arrives in the laboratory.
- Available STAT?
- No
Billing & Coding
- CPT codes
- Billing Comments
For additional test/billing information, see following page, CPT codes for Hereditary Cancer Panels (germline and paired).
For pricing information, contact Client Support Services 206-520-4600 or 800-713-5198.
Billing and Insurance Pre-Authorization
We offer insurance pre-authorization services (preauthorization is only done for providers who are external to the UW system).
Email: gpab@uw.edu or call 1-855-320-4869 for more information.
A letter of medical necessity is highly recommended for ColoSeq™ Tumor testing, and a template is available by emailing genelab@uw.edu.
- LOINC
- 51967-8
- Interfaced Order Code
- UOW2961